Status:
UNKNOWN
Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis
Lead Sponsor:
Sheba Medical Center
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus \[CMV\]), herpes simplex virus type 1 (HSV-1) and herpes sim...
Detailed Description
The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus \[CMV\]), herpes simplex virus type 1 (HSV-1) and herpes sim...
Eligibility Criteria
Inclusion
- Definite multiple sclerosis
Exclusion
- Intravenous immune globulin (IVIg) treatment
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00230204
Start Date
September 1 2005
End Date
April 1 2006
Last Update
February 16 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Sclerosis Center, Sheba Medical Center
Ramat Gan, Israel, 52621